Moschamine
CAS No. 68573-23-9
Moschamine ( )
Catalog No. M31297 CAS No. 68573-23-9
Moschamine is a very potent compound that is able to inhibit COX-I by 58% and COX-II by 54%, at the concentration of 0.1 μmol L⁻1, it may suppress cAMP formation via binding to 5-HT1 receptors in the cells. Moschamine exerts antitumour effects on HeLa, MCF7 and A431 cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 299 | In Stock |
|
50MG | Get Quote | In Stock |
|
100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameMoschamine
-
NoteResearch use only, not for human use.
-
Brief DescriptionMoschamine is a very potent compound that is able to inhibit COX-I by 58% and COX-II by 54%, at the concentration of 0.1 μmol L⁻1, it may suppress cAMP formation via binding to 5-HT1 receptors in the cells. Moschamine exerts antitumour effects on HeLa, MCF7 and A431 cells.
-
DescriptionMoschamine is a very potent compound that is able to inhibit COX-I by 58% and COX-II by 54%, at the concentration of 0.1 μmol L⁻1, it may suppress cAMP formation via binding to 5-HT1 receptors in the cells. Moschamine exerts antitumour effects on HeLa, MCF7 and A431 cells.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number68573-23-9
-
Formula Weight352.4
-
Molecular FormulaC20H20N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
L-701252
glycine-NMDA site antagonist.
-
ACT-389949
ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes.
-
CP94253 hydrochlorid...
CP94253 hydrochloride is a potent, selective and centrally active agonist of 5-HT1B receptor with Ki of 2 nM. The Kis are 89, 49, 860, and 1600 nM for 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors, respectively.